MA39841A - Association d'un inhibiteur de l'egfr et d'un inhibiteur de mek dans le traitement de cancers présentant une mutation de nras - Google Patents

Association d'un inhibiteur de l'egfr et d'un inhibiteur de mek dans le traitement de cancers présentant une mutation de nras

Info

Publication number
MA39841A
MA39841A MA039841A MA39841A MA39841A MA 39841 A MA39841 A MA 39841A MA 039841 A MA039841 A MA 039841A MA 39841 A MA39841 A MA 39841A MA 39841 A MA39841 A MA 39841A
Authority
MA
Morocco
Prior art keywords
inhibitor
treatment
combination
mutated cancer
nras mutated
Prior art date
Application number
MA039841A
Other languages
English (en)
Inventor
Darren Anthony Edward Cross
Catherine Anne Eberlein
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd filed Critical Astrazeneca Ab
Publication of MA39841A publication Critical patent/MA39841A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés destinés à identifier une résistance à un traitement anticancéreux, en identifiant une mutation e63k de nras, une mutation g12v de nras ou une augmentation du nombre de copies du gène
MA039841A 2014-04-04 2015-04-02 Association d'un inhibiteur de l'egfr et d'un inhibiteur de mek dans le traitement de cancers présentant une mutation de nras MA39841A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461975088P 2014-04-04 2014-04-04
US201462013573P 2014-06-18 2014-06-18

Publications (1)

Publication Number Publication Date
MA39841A true MA39841A (fr) 2017-02-08

Family

ID=52824498

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039841A MA39841A (fr) 2014-04-04 2015-04-02 Association d'un inhibiteur de l'egfr et d'un inhibiteur de mek dans le traitement de cancers présentant une mutation de nras

Country Status (15)

Country Link
US (2) US20200237758A1 (fr)
EP (1) EP3125885B1 (fr)
JP (1) JP6549147B2 (fr)
KR (1) KR102406334B1 (fr)
CN (1) CN106456774A (fr)
AU (1) AU2015242407B2 (fr)
CA (1) CA2943402C (fr)
DK (1) DK3125885T3 (fr)
ES (1) ES2890556T3 (fr)
HU (1) HUE055747T2 (fr)
MA (1) MA39841A (fr)
MX (1) MX369111B (fr)
PL (1) PL3125885T3 (fr)
RU (1) RU2683276C2 (fr)
WO (1) WO2015150826A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102444835B1 (ko) 2016-05-26 2022-09-19 리커리엄 아이피 홀딩스, 엘엘씨 Egfr 억제제 화합물
WO2018218633A1 (fr) * 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Polythérapies pour le traitement de cancers
WO2019195959A1 (fr) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Polythérapie pour cancers à mutation de braf

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492568A1 (fr) * 2002-04-08 2005-01-05 SmithKline Beecham Corporation Methode de traitement du cancer consistant a administrer un inhibiteur de la famille erb et un inhibiteur de raf et/ou de ras
AU2009314336B2 (en) * 2008-11-11 2013-09-12 Eli Lilly And Company P70 S6 kinase inhibitor and EGFR inhibitor combination therapy
JP5427321B2 (ja) * 2011-07-27 2014-02-26 アストラゼネカ アクチボラグ ２−（２，４，５−置換−アニリノ）ピリミジン化合物
CN104093743B (zh) * 2011-11-23 2018-04-24 医学免疫有限责任公司 特异于her3的结合分子及其用途
US20150071918A1 (en) * 2012-05-09 2015-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptides for the treatment of cancer
EP2884971A4 (fr) * 2012-08-16 2016-01-06 Ohio State Innovation Foundation Inhibiteurs de stat3 et leur utilisation anticancéreuse
US20140066465A1 (en) * 2012-09-04 2014-03-06 The Cleveland Clinic Foundation CANCER TREATMENT USING TYROSINE KINASE AND NF-kB INHIBITORS

Also Published As

Publication number Publication date
KR20160135362A (ko) 2016-11-25
RU2016140626A3 (fr) 2018-10-23
PL3125885T3 (pl) 2021-12-06
WO2015150826A1 (fr) 2015-10-08
DK3125885T3 (da) 2021-09-27
EP3125885B1 (fr) 2021-06-30
JP6549147B2 (ja) 2019-07-24
CA2943402C (fr) 2022-12-13
RU2683276C2 (ru) 2019-03-27
KR102406334B1 (ko) 2022-06-07
US20200237758A1 (en) 2020-07-30
AU2015242407B2 (en) 2017-11-09
JP2017511341A (ja) 2017-04-20
MX2016013048A (es) 2017-04-27
AU2015242407A1 (en) 2016-10-13
CA2943402A1 (fr) 2015-10-08
US20210177844A1 (en) 2021-06-17
HUE055747T2 (hu) 2021-12-28
RU2016140626A (ru) 2018-05-07
EP3125885A1 (fr) 2017-02-08
CN106456774A (zh) 2017-02-22
MX369111B (es) 2019-10-29
ES2890556T3 (es) 2022-01-20

Similar Documents

Publication Publication Date Title
ZA201701491B (en) Methods and therapeutic combinations for treating tumors
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2017000546A (es) Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek.
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
EP3206987A4 (fr) Nanoparticules pour thérapie photodynamique, thérapie photodynamique induite par rayons x, radiothérapie, chimiothérapie, immunothérapie, et toute combinaison de celles-ci
SG10202103475XA (en) Methods and compositons for treating cancer
ZA201902320B (en) 17alpha,21-diesters of cortexolone for use in the treatment of tumors
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
MX2014005800A (es) Mutaciones del receptor notch humano y su uso.
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
MX2016002857A (es) Uso de una combinacion de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
MX2016013600A (es) Método para tratar adenocarcinoma de pulmón.
EP3126525A4 (fr) Procédé et kits d'identification d'inhibiteurs de cdk9 pour le traitement du cancer
PH12017500881B1 (en) Aurora a kinase inhibitor
EP3152560A4 (fr) Détection de mutation génique non-effractive chez des patients atteints du cancer du poumon
GB201509226D0 (en) Molecular and bioinformatics methods for direct sequencing
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
EP3531830A4 (fr) Méthodes et compositions d'identification et de traitement de patients atteints d'un cancer du poumon à petites cellules
MA39841A (fr) Association d'un inhibiteur de l'egfr et d'un inhibiteur de mek dans le traitement de cancers présentant une mutation de nras
MX2016012244A (es) Compuestos y sus metodos de uso.
WO2018081817A3 (fr) Ciblage de microarn-101-3 p dans une cancérothérapie
EP3371211A4 (fr) Méthodes de traitement de tumeurs et du cancer, et identification de sujets candidats à ce traitement